Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 versus intravesical gemcitabine or mitomycin C for recurrent high-risk non-muscle-invasive bladder cancer after BCG
ISRCTN72352492Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine-releasing intravesical system, gemcitabine and mitomycin c in non-muscle-invasive bladder cancer (NMIBC), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival. Started Apr 2024; status: recruiting.
02
Drugs
gemcitabine-releasing intravesical systemgemcitabinemitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ISRCTN72352492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72352492.